• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    OpGen Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    12/6/24 5:03:26 PM ET
    $OPGN
    Medical Specialities
    Health Care
    Get the next $OPGN alert in real time by email
    false 0001293818 0001293818 2024-12-04 2024-12-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the
    Securities Exchange Act of 1934

     

    December 4, 2024
    Date of Report (date of earliest event reported)

     

     

     

    OpGen, Inc.

    (Exact name of Registrant as specified in its charter)

     

     

     

    Delaware

     

    001-37367

     

    06-1614015

    (State or other jurisdiction of
    incorporation or organization)
      (Commission
    File Number)
     

    (I.R.S. Employer
    Identification Number)

     

    23219 Stringtown Road, Suite 300

    Clarksburg, MD 20871
    (Address of principal executive offices)(Zip code)

     

    (240) 813-1260
    (Registrant’s telephone number, including area code)

     

    Not Applicable
    (Former name or former address, if changed since last report)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock   OPGN   The Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On December 4, 2024, the Board of Directors of OpGen, Inc. (the “Company”) appointed Mohd Azham Azudin as Chief Operating Officer of the Company and Gillian Tan Rou Yee as Company Secretary of the Company.

     

    Mr. Azudin, age 52, has over 25 years of investment experience specifically in private equity, venture capital deals, and corporate advisory, including corporate structuring, finance and mergers and acquisitions. Since March 2023, he has served as Vice President of Group Investments and Corporate Advisory at AEI Capital Ltd. Mr. Azudin will retain such role, however, in such capacity, he will also serve as the Chief Operating Officer of the Company. Prior to his current role, from September 2022 to January 2023, Mr. Azudin served as the Lead Executioner for the Security Token Offering (“STO”) Division at ATA Global Inc. US. From March 2021 to June 2021, Mr. Azudin was involved in the F&B Fund Framework and Conceptualization Paper at Articulate Fusion Sdn. Bhd. Mr. Azudin served as Vice President in Private Equity Investments at Malaysian Development Bank’s Private Equity Management Company from 2007 to 2010 and as the Executive Vice President in Corporate Affairs at Quest MasteryAsia Group from 2017 to 2021. Mr. Azudin holds a chartered accountant designation from the Malaysia Institute of Accountants.

     

    In connection with his appointment, on December 4, 2024, the Company entered into a Consulting Agreement with Mr. Azudin (the “Azudin Consulting Agreement”), pursuant to which he will serve as the Chief Operating Officer. The Azudin Consulting Agreement provides that Mr. Azudin will receive a base salary of $50,000 per year. Under the Azudin Consulting Agreement, the Company may elect to pay such base salary, or a portion thereof, by granting Mr. Azudin equity securities of the Company.

     

    The foregoing summary of certain terms of the Azudin Consulting Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the agreement, which is attached to this Current Report on Form 8-K as Exhibit 10.1 and is incorporated herein by reference.

     

    Ms. Tan, age 27, is a legal professional, who earned her LLB degree from the University of the West of England, Bristol, in 2019. Following her undergraduate studies, Ms. Tan pursued further education at the City Law School, University of London, where she completed the Bar Professional Training Course (BPTC) and obtained a Master’s in Law, in 2020 and 2021, respectively. Ms. Tan began her legal career when she was called to the Bar of England and Wales at Lincoln’s Inn in 2020. She completed her chambering in 2021 at Messrs. Gideon Tan Razali Zaini, focusing on litigation. In 2022, she completed her chambering and was called to the Malaysian Bar as an advocate and solicitor of the High Court of Malaya, and she subsequently practiced as a lawyer specializing in corporate-commercial law until 2023 at Messrs. J.M. Chong, Vincent Chee & Co. as a Legal Associate. In April 2024, Ms. Tan transitioned to her current role as In-House Lead Counsel at AEI Capital Group. In this position, she leverages her expertise in corporate law to contribute significantly to the organization’s legal strategies.

     

    In connection with her appointment, on December 4, 2024, the Company entered into a Consulting Agreement with Ms. Tan (the “Tan Consulting Agreement”), pursuant to which she will serve as Company Secretary. The Tan Consulting Agreement provides that Ms. Tan will receive a base salary of $25,000 per year. Under the Consulting Agreement, the Company may elect to pay such base salary, or a portion thereof, by granting Ms. Tan equity securities of the Company.

     

    The foregoing summary of certain terms of the Tan Consulting Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the agreement, which is attached to this Current Report on Form 8-K as Exhibit 10.2 and is incorporated herein by reference.

     

    1

     

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit Number   Description
    10.1   Consulting Agreement, dated December 4, 2024, by and between the Company and Mohd Azham Azudin
    10.2   Consulting Agreement, dated December 4, 2024, by and between the Company and Gillian Tan Rou Yee
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Date: December 6, 2024 OpGen, Inc.
         
      By: 

    /s/ John Tan Honjian

        Name:  John Tan Honjian
        Title: Chairman and Chief Executive Officer

     

    3

    Get the next $OPGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OPGN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OPGN
    Financials

    Live finance-specific insights

    See more
    • OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update

      Total revenue for the first half of 2023 was approximately $1.65 million, an increase of approximately 15% compared to approximately $1.44 million in the first half of 2022Signed FIND R&D collaboration contract extensionEntered distribution agreement with Fisher Healthcare for the distribution of the Unyvero A50 platform in the U.S.Management conference call is scheduled for August 10, 2023, at 4:30 p.m. ET ROCKVILLE, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its second quarter and first half of 2023 f

      8/10/23 4:15:00 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time

      ROCKVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) ("OpGen" or "the Company") announced today that the Company will provide a business update and report its second quarter 2023 financial results after the close of the U.S. financial markets on Thursday, August 10th 2023. OpGen's management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide an update on business activities. Conference Call Details       U.S. Dial-in Number:   1-877-704-4453       International Dial-in Number: 1-201-389-0920      Webcast:   https://viavid.webcasts.com/starthere.jsp?ei=1618010&tp_key=fc7c8907d6  Re

      8/3/23 7:30:00 AM ET
      $OPGN
      Medical Specialities
      Health Care
    • OpGen Reports First Quarter 2023 Financial Results and Provides Business Update

      Total revenue for the first quarter of 2023 was approximately $0.91 million, an increase of approximately 94% compared to the first quarter of 2022Expanded U.S. growth opportunities with the Unyvero UTI De Novo FDA submission and Unyvero distribution partnership with Fisher HealthcareMet all remaining key milestones of the FIND collaboration for Unyvero A30Management conference call scheduled for May 15, 2023, at 4:30 p.m. EST ROCKVILLE, Md., May 15, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its first quarter 20

      5/15/23 4:15:00 PM ET
      $OPGN
      Medical Specialities
      Health Care

    $OPGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Technology Officer (CTO) Syed Mohd Syed Johan Bin was granted 9,709 shares (SEC Form 4)

      4 - OPGEN INC (0001293818) (Issuer)

      4/30/25 4:32:10 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Syed Mohd Syed Johan Bin

      3 - OPGEN INC (0001293818) (Issuer)

      4/30/25 4:30:31 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • Director Wong Poh Yin Constance was granted 28,571 shares (SEC Form 4)

      4 - OPGEN INC (0001293818) (Issuer)

      12/19/24 4:34:06 PM ET
      $OPGN
      Medical Specialities
      Health Care

    $OPGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright resumed coverage on OpGen with a new price target

      HC Wainwright resumed coverage of OpGen with a rating of Buy and set a new price target of $4.00

      3/15/21 7:37:07 AM ET
      $OPGN
      Medical Specialities
      Health Care
    • Alliance Global Partners reiterated coverage on OpGen with a new price target

      Alliance Global Partners reiterated coverage of OpGen with a rating of Buy and set a new price target of $7.00 from $5.65 previously

      3/8/21 8:22:12 AM ET
      $OPGN
      Medical Specialities
      Health Care
    • Alliance Global Partners reiterated coverage on OpGen with a new price target

      Alliance Global Partners reiterated coverage of OpGen with a rating of Buy and set a new price target of $7.00 from $5.65 previously

      3/2/21 10:53:18 AM ET
      $OPGN
      Medical Specialities
      Health Care

    $OPGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q

      ROCKVILLE, Md., May 24, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))) announced today that it received a notice from The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the Company not filing its Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the "Form 10-Q"), which serves as an additional basis for delisting the Company's securities from Nasdaq, and that the Nasdaq Hearings Panel will consider this matter in connection with the continued listing of the Company's securities on Nasdaq. Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all

      5/24/24 4:04:59 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • OpGen Announced 1-for-10 Reverse Stock Split

      ROCKVILLE, Md., May 16, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))) today announced that the Company's board of directors has approved a 1-for-10 reverse stock split of its shares of common stock (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 12:01 a.m. EST on May 20, 2024 and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis under the Company's existing trading symbol "OPGN." The new CUSIP number for the Company's common stock following the Reverse Stock Split will be 68373L505. OpGen expects that the Reverse Stock Split, which was approved by its stockholders at a Special

      5/16/24 7:00:00 AM ET
      $OPGN
      Medical Specialities
      Health Care
    • OpGen Provides Update on Business Operations and Strategic Opportunities

      ROCKVILLE, Md., April 29, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))) announced today that it entered into an agreement to sell its commercial customer contracts and installed base of Unyvero systems to Camtech Pte Ltd ("Camtech"), a Singaporean family office for $218,000. The transaction follows Camtech's prior acquisition of all of Curetis GmhH's ("Curetis"), the Company's subsidiary, Unyvero assets, rights and businesses, as part of Curetis' insolvency proceedings. In addition, the Company's subsidiary, Ares Genetics GmbH, sold all of its assets, including the ARESdb database and intellectual property portfolio to bioMerieux S.A., as part of Are

      4/29/24 4:05:00 PM ET
      $OPGN
      Medical Specialities
      Health Care

    $OPGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by OpGen Inc.

      SC 13D/A - OPGEN INC (0001293818) (Subject)

      8/1/24 5:25:39 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by OpGen Inc. (Amendment)

      SC 13D/A - OPGEN INC (0001293818) (Subject)

      4/25/24 5:43:11 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by OpGen Inc. (Amendment)

      SC 13D/A - OPGEN INC (0001293818) (Subject)

      4/8/24 4:05:12 PM ET
      $OPGN
      Medical Specialities
      Health Care

    $OPGN
    SEC Filings

    See more
    • OpGen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - OPGEN INC (0001293818) (Filer)

      5/29/25 5:20:29 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • SEC Form NT 10-Q filed by OpGen Inc.

      NT 10-Q - OPGEN INC (0001293818) (Filer)

      5/16/25 4:39:39 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • SEC Form NT 10-K filed by OpGen Inc.

      NT 10-K - OPGEN INC (0001293818) (Filer)

      3/31/25 5:00:19 PM ET
      $OPGN
      Medical Specialities
      Health Care

    $OPGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Aei Capital Ltd bought $1,916,326,200,000 worth of shares (2,400,000 units at $798,469.25) (SEC Form 4)

      4 - OPGEN INC (0001293818) (Issuer)

      12/10/24 12:32:18 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • Large owner Aei Capital Ltd bought $11,130,140,980,409 worth of shares (5,245,603 units at $2,121,803.91) (SEC Form 4)

      4 - OPGEN INC (0001293818) (Issuer)

      10/8/24 6:51:09 PM ET
      $OPGN
      Medical Specialities
      Health Care